In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Julian Casciano, President & CEO at eMAX Health.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Julian, covering:

How a family tragedy led him into the healthcare and pharmaceutical world.
Why corporate life was not for him, but the valuable lessons he learned during his time at KPMG.
The turbulent journey with a venture capital partner that ultimately led to an IPO and a successful first exit.
How a relentless drive to become truly technology enabled has resulted in sixty percent of company revenue now coming from tech driven solutions.
What led him to partner with private equity to accelerate investment in a game changing technology platform.
Why the future of the sector is unfolding at speed right in front of us, and why now is the time to jump on board.

As Chairman and Chief Executive Officer, Julian leads eMAX Health’s mission to modernize market access and patient services for pharmaceutical and biotech innovators. With a background in technology enabled pharmaceutical services, commercialization strategy, patient services, and entrepreneurship, he has built the organisation into a trusted partner for navigating the complexity of rapidly evolving medical and commercial programs.

Most recently, Julian spearheaded the launch of MAVA®, a proprietary digital platform delivering rapid stakeholder insights and pricing guidance powered by real time data and AI. He also architected eMAX Health’s proprietary patient services case management system, HealthPACER®.

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

The 30-year, overnight success